August 19, 2017 7:31 PM ET


Company Overview of Sprout Pharmaceuticals, Inc.

Company Overview

Sprout Pharmaceuticals, Inc. develops and offers products for treatment of female sexual health. It offers a non-hormonal pill for the treatment of acquired and generalized hypoactive sexual desire disorder in premenopausal women in the United States. The company was founded in 2011 and is based in Raleigh, North Carolina. As of October 1, 2015, Sprout Pharmaceuticals, Inc. operates as a subsidiary of Valeant Pharmaceuticals International, Inc.

4208 Six Forks Road

Suite 1010

Raleigh, NC 27609

United States

Founded in 2011





Key Executives for Sprout Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer and Director
Co-Founder and Vice Chairman
Age: 66
Executive Vice President of Commercial Strategy
Executive Vice President of Corporate and Regulatory Affairs
Secretary and Director
Compensation as of Fiscal Year 2017.

Sprout Pharmaceuticals, Inc. Key Developments

Sprout Pharmaceuticals, Inc. Announces Addyi

Sprout Pharmaceuticals, Inc. announced that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies. Addyi was approved by the U.S. Food and Drug Administration (FDA) on August 18, 2015. The company will offer two avenues of affordable access for women, including the Addyi Affordable Access Card for pharmacies and the AddyiDirect program with doorstep delivery. The approval of Addyi is largely based on three North American, Phase 3, 24-week, randomized double blind, placebo-controlled studies of premenopausal women with HSDD. Addyi was administered to over 2,500 premenopausal women with acquired, generalized HSDD in clinical trials, with over 850 receiving treatment for at least 12 months. For premenopausal women with HSDD, Addyi has demonstrated improvements in desire for sex, reducing distress from the loss of sexual desire and increasing the number of satisfying sexual events. Addyi is not indicated for use in postmenopausal women or men or to enhance sexual function. Addyi was approved with a Boxed Warning. Use of Addyi with alcohol increases the risk of severe hypotension and syncope; therefore, alcohol use is contraindicated. Severe hypotension and syncope occurs when Addyi is used with moderate or strong CYP3A4 inhibitors or in patients with hepatic impairment; therefore use of Addyi in patients with hepatic impairment is also contraindicated. Hypotension, syncope and central nervous system (CNS) depression can occur with Addyi alone. The most common adverse reactions are dizziness, somnolence, nausea, fatigue, insomnia and dry mouth. See full safety information below. Addyi is intended to be administered orally once per day at bedtime with or without food.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sprout Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at